MARKET

BIIB

BIIB

Biogen Inc
NASDAQ
216.03
+14.07
+6.97%
Pre Market: 216.91 +0.88 +0.41% 08:31 06/29 EDT
OPEN
202.53
PREV CLOSE
201.96
HIGH
218.06
LOW
202.29
VOLUME
943
TURNOVER
176.53M
52 WEEK HIGH
218.06
52 WEEK LOW
121.05
MARKET CAP
31.89B
P/E (TTM)
23.18
1D
5D
1M
3M
1Y
5Y
1D
Xilio Therapeutics names Ben Harshbarger chief legal officer
PUBT · 1h ago
Kailera Therapeutics names Kathleen Tregoning chief corporate affairs officer
PUBT · 1h ago
Biogen To Present New Data Across Alzheimer’s Disease Portfolio At AAIC 2026, Presentations To Include Data From Phase 2 CELIA Study Evaluating Diranersen, And New Analyses From Studies Of LEQEMBI
Benzinga · 1h ago
Biogen to present Phase 2 CELIA data for tau-targeting Alzheimer’s drug diranersen at AAIC 2026
PUBT · 1h ago
Analyst Reaffirms Buy on Biogen, Nudges Price Target to $256 on Strong Spinraza HD Momentum and Pipeline Progress
TipRanks · 2h ago
Biogen Price Target Raised to $256.00/Share From $255.00 by Needham
Dow Jones · 2h ago
BIOGEN <BIIB.O>: NEEDHAM RAISES TARGET PRICE TO $256 FROM $255
Reuters · 2h ago
Weekly Report: what happened at BIIB last week (0622-0626)?
Weekly Report · 3h ago
More
About BIIB
Biogen Inc. is a biotechnology company. The Company is focused on discovering, developing and delivering therapies. It has a portfolio of medicines to treat Multiple Sclerosis (MS), has introduced an approved treatment for Spinal Muscular Atrophy (SMA), co-developed treatments to address a defining pathology of Alzheimer's disease and launched an approved treatment to target a genetic cause of Amyotrophic Lateral Sclerosis (ALS). It markets a drug approved in United States, European Union and certain international markets for the treatment of Friedreich Ataxia (FA) in adults and adolescents aged 16 years and older. It is focused on advancing its pipeline in neurology, specialized immunology and rare diseases. Its marketed products include VUMERITY, TYSABRI, TECFIDERA, AVONEX and PLEGRIDY for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of FA, and QALSODY for the treatment of ALS. Its commercialized products also include EMPAVELI and SYFOVRE.

Webull offers Biogen Inc stock information, including NASDAQ: BIIB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BIIB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BIIB stock methods without spending real money on the virtual paper trading platform.